L-多巴测试对皮质醇反应的影响及其与胰岛素耐受性测试 (比较临床研究) 的比较
Fatma Özgüç Çömlek1,2, Hümeyra Yaşar Köstek1, Emine Dilek1
1Division of Pediatric Endocrinology, School of Medicine, Trakya University, Edirne, Türkiye.
Medicine
|September 9, 2025
概括
L-多巴测试有效地刺激皮质醇释放,类似于胰岛素耐受性测试 (ITT),使其成为评估儿童下丘脑-垂体-上腺 (HPA) 轴的潜在更安全的替代方案.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 内分泌检测是指内分泌检测.
- 激素轴评价的评估
背景情况:
- 下垂体-垂体-上腺 (HPA) 轴对应激反应和新陈代谢至关重要.
- 胰岛素耐受性测试 (ITT) 是HPA轴评估的黄金标准,但在儿童中存在低血糖风险.
- L-dopa在刺激上腺皮质激素和皮质醇释放方面显示出潜在的潜力.
研究的目的:
- 评估L-多巴测试在引起矮小儿童皮质醇反应方面的有效性.
- 为了将L-多巴测试的性能与HPA轴评估的ITT进行比较.
- 为了确定L-dopa是否可以作为ITT更安全的替代品.
主要方法:
- 这项研究涉及向矮小的儿童注射L-多巴和ITT.
- 血液样本以 (0,30,60,90,120分钟) 的间隔收集,以测量生长激素和皮质醇水平.
- 充分的HPA轴反应被定义为血清皮质醇水平>18μg/dL.
主要成果:
- 100%的儿童对ITT显示出足够的皮质醇反应 (>18μg/dL).
- 90%的儿童通过L-多巴测试获得了足够的皮质醇反应.
- 皮质醇水平在L-dopa (70%) 的第120分钟和ITT (65%) 的第60分钟达到峰值.
结论:
- L-多巴刺激测试有效评估HPA轴,并刺激皮质醇水平,与ITT相比.
- 对于HPA轴监测,L-dopa提供了一种可行的,可能更安全的ITT替代方案,特别是当ITT带有风险时.
- 这一发现支持在儿科内分泌评估中使用L-多巴测试.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
71.4K
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.7K
相关概念视频
01:16Insulin: Dosing Regimen and Adverse Effects
695
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
695
01:15Hypoglycemia and Glucagon
839
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
839